Speakers 2016
-
NORTH & WEST (chairman)
Presentation
-
-
State of the art lecture (chairman)
-
How to improve the therapeutic strategies?
-
Can we expect eradication in HCV G4?
Presentation
-
-
Staging of steatosis and fibrosis: liver biopsy or indirect markers? (chairman)
Presentation
-
BELHADJ BRIK Najet
Tunisia
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop)
Presentation
-
-
Traitements des patients atteints de cirrhose (French speaking lunch workshop)
Presentation
-
-
How to optimize therapy? (chairman)
-
New therapeutic strategies (chairman)
-
State of the art lecture (chairman)
-
How to optimize treatment in G3 patients? (chairman)
-
Take home message
Presentation
-
-
Traitements des patients atteints de cirrhose (French speaking lunch workshop) (chairman)
Presentation
-
-
Is the benefit to treat patients with cirrhosis proven?
Presentation
-
-
Special populations (chairman)
Presentation
-
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
-
Staging of steatosis and fibrosis: liver biopsy or indirect markers?
-
What's new in hepatitis B? (chairman)
Presentation
-
-
NORTH & WEST (chairman)
-
Take home messages
-
How to optimize treatment in G3 patients?
-
Treatment of hepatocellular carcinoma: beyond international guidelines
Presentation
-
-
Who to treat? (chairman)
-
Why do I treat my patients with mild hepatitis?
-
Clinical applications of HBsAg quantification
Presentation
-
-
NORTH & WEST
-
Staging of steatosis and fibrosis: liver biopsy or indirect markers? (chairman)
Presentation
-
-
Traitement HBV : Interféron ou analogues? (French speaking lunch workshop)
Presentation
-
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop) (chairman)
Presentation
-
DI BISCEGLIE Adrian
USA
-
How to manage relapsers and non-responders to PEG-IFN + RBV therapy? (chairman)
-
End-stage liver disease is a multifaceted condition (chairman)
Presentation
-
DI MARTINO Vincent
France
-
Are DAAs therapies associated with HCV eradication?
Presentation
-
-
Treatment of HCV cirrhosis and transplanted patients: when and how?
-
Special populations (chairman)
Presentation
-
El RAY Ahmed
Egypt
-
SOUTH & EAST
Presentation
-
-
Can we expect eradication in HCV G4? (chairman)
Presentation
-
-
NORTH & WEST
Presentation
-
ESTRABAUD Emilie
France
-
Are DAAs therapies associated with HCV eradication?
Presentation
-
-
How to optimize the strategy against HCV? (chairman)
-
How to manage relapsers and non-responders to PEG-IFN + RBV therapy? (chairman)
Presentation
-
FLISIAK Robert
Poland
-
SOUTH & EAST (chairman)
-
Need to assess HCV resistance profile before the initiation of DAAs therapy?
Presentation
-
-
Individual optimization of therapy (shorten therapy)
-
NORTH & WEST
-
First line therapy of hepatitis B: interferon or analogues? (chairman)
Presentation
-
-
Traitements des patients atteints de cirrhose (French speaking lunch workshop)
Presentation
-
-
The influence of therapy on the burden of hepatitis C
-
How to optimize treatment in G3 patients? (chairman)
Presentation
-
-
SOUTH & EAST (chairman)
-
Future therapies for HBV and HDV: what can we expect?
-
Optimal therapy of chronic hepatitis B (chairman)
Presentation
-
GINES Pere
Spain
-
Management of uninfected and infected ascites in cirrhosis
Presentation
-
GOURNAY Jérôme
France
-
How to optimize treatment in G3 patients?
Presentation
-
-
Clinical applications of HBsAg quantification (chairman)
Presentation
-
-
Why don’t I treat my patients with mild hepatitis?
-
Need to assess HCV resistance profile before the initiation of DAAs therapy?
Presentation
-
HORBAN Andrzej
Poland
-
How to manage relapsers and non-responders to PEG-IFN + RBV therapy?
Presentation
-
-
SOUTH & EAST
Presentation
-
-
Clinical applications of HBsAg quantification (chairman)
-
Optimal therapy of chronic hepatitis B (chairman)
-
Which pregnant women to treat?
Presentation
-
-
First line therapy of hepatitis B: interferon or analogues? (chairman)
-
New therapeutic perspectives?
Presentation
-
-
Prognosis and management of inactive carriers
Presentation
-
LEROY Vincent
France
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop)
Presentation
-
-
Future therapies for HBV and HDV: what can we expect?
Presentation
-
-
How to optimize therapy? (chairman)
-
Future therapies for HBV and HDV: what can we expect? (chairman)
Presentation
-
MANNS Michael
Germany
-
NORTH & WEST
-
Future therapies for HBV and HDV: what can we expect? (chairman)
-
New therapeutic strategies (chairman)
Presentation
-
-
Introduction: Treatment of hepatitis C: Access to eradication !
-
Conclusion
-
Introduction: Hepatitis B, the come back?
-
State of the art lecture and award (chairman)
-
Conclusion
Presentation
-
-
Virological markers for the management of patients
Presentation
-
MATHURIN Philippe
France
-
First line therapy of hepatitis B: interferon or analogues?
-
HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop) (chairman)
Presentation
-
-
End-stage liver disease is a multifaceted condition (chairman)
Presentation
-
MOUCARI Rami
United Arab Emirates
-
Clinical applications of HBsAg quantification
Presentation
-
-
How to provide the best treat with what is available?
Presentation
-
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)
Presentation
-
PAGEAUX Georges-Philippe
France
-
Treatment of HCV cirrhosis and transplanted patients: when and how?
Presentation
-
PAIS Raluca
France
-
Management and treatment of NASH
Presentation
-
-
First line therapy of hepatitis B: interferon or analogues?
-
Do I treat my immunotolerant patients?
Presentation
-
-
SOUTH & EAST
Presentation
-
-
Hepatitis E : the neglected one
Presentation
-
PIETRANGELO Antonello
Italy
-
Management and treatment of NASH (chairman)
-
Iron and the liver
Presentation
-
-
Who to treat? (chairman)
-
HIV-HCV coinfections (chairman)
-
Patients with chronic Kidney diseases
Presentation
-
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)
Presentation
-
RATZIU Vlad
France
-
Management and treatment of NASH (chairman)
Presentation
-
-
The adventure of Delta
Presentation
-
SALMON Dominique
France
-
HIV-HCV coinfections
Presentation
-
-
Treatment of HCV cirrhosis and transplanted patients: when and how? (chairman)
-
DAAs and transplanted patients
Presentation
-
-
How to optimize the strategy against HCV? (chairman)
Presentation
-
SERFATY Lawrence
France
-
Follow-up of patients with SVR
-
Are DAAs therapies associated with HCV eradication? (chairman)
Presentation
-
-
Universal screening?
-
Are DAAs therapies associated with HCV eradication? (chairman)
Presentation
-
SOGNI Philippe
France
-
Traitement HBV : Interféron ou analogues? (French speaking lunch workshop)
Presentation
-
-
HIV-HCV coinfections (chairman)
-
HIV-HCV co-infected patients
Presentation
-
TRAN Albert
France
-
HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)
Presentation
-
-
Traitement HBV : Interféron ou analogues? (French speaking lunch workshop) (chairman)
Presentation
-
TSERTSVADZE Tengiz
Georgia
-
SOUTH & EAST
Presentation
-
URBANEK Petr
Czech Republic
-
Management and treatment of NASH
Presentation
-
VALLA Dominique
France
-
Treatment of HCV cirrhosis and transplanted patients: when and how? (chairman)
Presentation
-
-
SOUTH & EAST
-
Traitements des patients atteints de cirrhose (French speaking lunch workshop) (chairman)
Presentation
-
-
Can we expect eradication in HCV G4?
Presentation
-
YAZDANPANAH Yazdan
France
-
HIV-HCV coinfections
Presentation
-
-
Traitement HBV : Interféron ou analogues? (French speaking lunch workshop) (chairman)
Presentation
-
ZEUZEM Stefan
Germany
-
Is it useful to detect resistance associated variants?
Presentation
-
-
How to manage relapsers and non-responders to PEG-IFN + RBV therapy?
Presentation
-
ZOULIM Fabien
France
-
What's new in hepatitis B? (chairman)
-
Clinical relevance of HBV cccDNA
-
Need to assess HCV resistance profile before the initiation of DAAs therapy? (chairman)
Presentation
-
